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Protocol
AbstrACt
Introduction Epidural analgesia provides an important 
synergistic method of pain control. In addition to 
reducing perioperative opioid consumption, the 
deliverance of analgesia into the epidural space, 
effectively creating a sympathetic blockade, has 
a multitude of additional potential benefits, from 
decreasing the incidence of postoperative delirium to 
reducing the development of persistent postsurgical 
pain (PPSP). Prior studies have also identified a 
correlation between the use of epidural analgesia 
and improved oncological outcomes and survival. The 
aim of this study is to evaluate the effect of epidural 
analgesia in pancreatic operations on immediate 
postoperative outcomes, the development of PPSP and 
oncological outcomes in a prospective, single-blind, 
randomised controlled trial.
Methods The Epidurals in Pancreatic Resection 
Outcomes (E-PRO) study is a prospective, single-
centre, randomised controlled trial. 150 patients 
undergoing either pancreaticoduodenectomy or distal 
pancreatectomy will be randomised to receive an 
epidural bupivacaine infusion following anaesthetic 
induction followed by continued epidural bupivacaine 
infusion postoperatively in addition to the institutional 
standardised pain regimen of hydromorphone 
patient-controlled analgesia (PCA), acetaminophen 
and ketorolac (intervention group) or no epidural 
infusion and only the standardised postoperative 
pain regimen (control group). The primary outcome 
was the postoperative opioid consumption, measured 
in morphine or morphine-equivalents. Secondary 
outcomes include patient-reported postoperative pain 
numerical rating scores, trend and relative ratios of 
serum inflammatory markers (interleukin (IL)-1β, 
IL-6, tumour necrosis factor-α, IL-10), occurrence 
of postoperative delirium, development of PPSP as 
determined by quantitative sensory testing, and 
disease-free and overall survival.
Ethics and dissemination The E-PRO trial has 
been approved by the institutional review board. 
Recruitment began in May 2016 and will continue until 
the end of May 2018. Dissemination plans include 
presentations at scientific conferences and scientific 
publications.




The utilisation of regional analgesia as a 
compliment to traditional pain manage-
ment techniques has become an increasingly 
common practice at many institutions. Placed 
preoperatively, epidural analgesia provides an 
important synergistic method of pain control 
postoperatively. In addition to its usefulness as 
a pain management adjunct, the deliverance 
of analgesia into the epidural space, effec-
tively creating a sympathetic blockade, has a 
multitude of potential additional benefits.
Previous studies have examined the use 
of epidurals in abdominal surgeries with a 
small number of retrospective trials focusing 
on the use of epidurals in pancreatic resec-
tions.1 While these retrospective studies 
demonstrated an improvement in patient-re-
ported pain scores postoperatively, objective 
measures are still needed to quantify these 
improvements in pain control.2 Prior studies 
have also highlighted a correlation between 
poor postoperative pain and the development 
of persistent postsurgical pain (PPSP).3–5 
As epidural analgesia creates a sympathetic 
blockade, its intraoperative and postopera-
tive use can mitigate the body’s inflammatory 
response and reduce the activation of periph-
eral and central nervous system pathways 
involved in the development of persistent pain 
syndromes.6 Interleukin-1-beta (IL-1β), IL-6 
and tumour necrosis factor-alpha (TNF-α) 
strengths and limitations of this study
 ► Strengths of this study include its design as 
a prospective randomised controlled trial and 
the length of longitudinal follow-up provided 
postoperatively. 
 ► Limitations include the single-institutional nature of 
this study.
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are three pro-inflammatory cytokines involved in the tran-
sition from acute pain states to chronic pain syndromes.7 
IL-10 is an anti-inflammatory cytokine that helps modu-
late the body’s stress response. IL-1β, IL-6, TNF-α and 
IL-10, and the relative balance of the pro-inflammatory 
and anti-inflammatory response, have all been implicated 
in nociceptive pathways and elevated levels have been 
found in chronic pain processes.8 While our current 
understanding of the complex modulation pathways of 
pain is limited, circulating IL-6 has been demonstrated 
in the upregulation of central and peripheral nocicep-
tive receptors, thereby generating the perception of pain, 
and potentially establishing the link between acute and 
chronic pain.9 10 This is of particular importance in our 
study population of patients with pancreatic diseases for 
whom adequate pain control is a critical factor in main-
taining good quality of life.11 12
In the immediate postoperative period, the use of 
epidural analgesia can improve other measures of patient 
recovery and healing, such as promoting gut motility 
and reducing the incidence of postoperative delirium. 
Along with reducing total opioid use, epidural analgesia 
produces a sympathectomy, allowing for dominance 
of the parasympathetic system, and further expediting 
the return of bowel function.13–15 With delayed gastric 
emptying as one of the most common complications and 
reasons for readmission after pancreatic resections, this 
valuable benefit of epidural analgesia requires further 
investigation.16 17 Delirium is another common postop-
erative complication that is associated with poor patient 
outcomes, including functional decline and death, and 
an effective prophylactic treatment remains to be iden-
tified. Through the effects of decreased intraoperative 
anaesthetic requirement and postoperative opioid use, 
epidural analgesia may have a potential protective role 
against postoperative delirium.
The effect of epidural analgesia in suppressing the 
inflammatory cascade is of particular interest to the 
field of oncology. In certain types of cancers, including 
pancreatic, the oncogenic process generates an inflam-
matory environment that propagates the growth of 
malignant lesions and continued inflammatory condi-
tions have been implicated in metastatic disease.18–20 
Pain can further exacerbate systemic inflammation.21 In 
additional to mitigating postsurgical pain, the sympa-
thectomy resulting from epidural analgesia also reduces 
the body’s overall inflammatory conditions.22 23 This 
attenuation of the heightened postoperative inflamma-
tory state of the body may provide an additional means 
of reducing progression of disease.
Pancreatic diseases
With improved detection and imaging modalities, the 
incidence of pancreatic disease, and subsequently, 
pancreatic operations, has increased.24–26 Pancreatic 
resection continues to be the primary surgical treat-
ment in the treatment of many benign and malignant 
pancreatic diseases, with an estimated 4000 operations 
performed annually in the USA.27 However, the mean 
5-year survival for malignant pancreatic disease remains 
the lowest of all cancers at 6%, with 70%–85% of patients 
dying of systemic recurrence, not just local disease.28–30 
While the search continues for earlier screening 
methods, the development of adjunctive therapies to 
surgical resection remains the most promising target of 
efforts to improve outcomes in malignant diseases of the 
pancreas. In particular, in recent years, a paradigm shift 
has occurred in the study of pancreatic malignancies 
where pancreatic cancer is viewed as a systemic disease, 
even in early stages, requiring a systemic approach in 
addition to regional disease control.31–34 In previous 
studies, primarily in prostate and colorectal malig-
nancies, the use of epidural analgesia has suggested a 
correlation with improved oncological outcomes and 
survival.35 36 Given the role between inflammation and 
cancer development and recurrence, and the sympa-
thetic blockade created by epidural analgesia, the 
significance of epidural analgesia in improving onco-
logical outcomes warrants continued investigation.
The aim of this study is to evaluate the effect of 
epidural analgesia in pancreatic operations on imme-
diate postoperative outcomes, the development of PPSP 




The Epidurals in Pancreatic Resection Outcomes 
(E-PRO) study is a prospective, single-centre, randomised 
controlled trial. In total, 150 patients undergoing either 
pancreaticoduodenectomy or distal pancreatectomy 
will be randomised to receive an epidural infusion of 
0.125% bupivacaine starting at 5 mL/hour (range of 
5–8 mL/hour) following anaesthetic induction followed 
by a standard epidural infusion of 0.1% bupivacaine at 
4–6 mL/hour postoperatively in addition to the institu-
tional standardised pain regimen of hydromorphone 
patient-controlled analgesia (PCA), intravenous acet-
aminophen and ketorolac (intervention group) or no 
epidural infusion and only the standardised postopera-
tive pain regimen (control group). Follow-up informa-
tion will be collected from the medical record for up to 
2 years postoperatively. The study design is outlined in 
figure 1.
Eligibility criteria
Patients 18 years old or older who are able to understand 
and sign an institutional review board (IRB)-approved 
informed consent form and who are undergoing either 
pancreaticoduodenectomy or distal pancreatectomy will 
be eligible for study inclusion. Patients will be excluded if 
they fulfil any one of the following criteria: indication for 
operative intervention being chronic pancreatitis, currently 
on warfarin with an international normalised ratio (INR) 
>1.4 or clopidogrel that cannot be discontinued 7 days prior 
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to surgery, most recent INR prior to surgery >1.4, most 
recent platelet count prior to surgery <70 000/μL, chronic 
opioid use as defined by use of >20 mg oxycodone, or equiv-
alent, daily, history of pre-existing neuropathic pain condi-
tions, known medical history of significant psychiatric or 
cognitive impairment, or history of HIV, hepatitis B and/or 
hepatitis C. Patients will be consented and enrolled during 
a clinic or preoperative evaluation appointment.
baseline assessment
Each study participant will be randomised into the control 
group with standard of care pain management regiment or 
the intervention group with the addition of epidural anal-
gesia. Randomisation will occur via a randomised number 
generation by the principal investigator (PI).
Patients will have the standard of care preoperative eval-
uation at the Barnes Jewish Hospital Center for Preoper-
ative Assessment and Planning. Routine laboratory tests 
including complete blood count, comprehensive meta-
bolic panel and coagulation studies will be obtained and 
reviewed.
In patients receiving chronic antiplatelet or antico-
agulant medications, the following procedure will be 
Figure 1 Study design. IL, interleukin; QST, quantitative sensory testing; TNF, tumour necrosis factor; VAS, visual analogue 
scores.
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practised to minimise the risk of bleeding (per Amer-
ican Society of Regional Anesthesia and Pain Medicine 
guidelines37).
Acetyl salicylic acid (aspirin) or other non-steroidal 
anti-inflammatory drugs may be continued prior to 
epidural catheter insertion. Clopidogrel use must be 
discontinued 7 days before the procedure. The study 
participant’s treating physician (eg, surgeon, cardiolo-
gist, neurologist) will be consulted prior to the discon-
tinuation of clopidogrel. Participants receiving warfarin 
will proceed with the following schedule: if INR <1.4, 
subject may proceed with epidural catheter insertion. 
If INR >1.4, the participant’s treating physician will be 
consulted whether warfarin can be discontinued until 
INR reaches <1.4 or the subject can be switched to 
low-molecular weight heparin, which can be discontinued 
36 hours before catheter insertion. INR and prothrombin 
time (PTT) will be assessed on the day of epidural cath-
eter insertion in all patients on anticoagulant (but not 
antiplatelet) therapy.
Study participants will undergo a complete medical 
history and physical examination, and the following base-
line assessments:
1. Evaluation of hypersensitivity or dynamic mechan-
ical allodynia to brush stimulation in the upper 
abdomen.38
2. Quantitative sensory testing (QST) to assess warm and 
cold detection thresholds, heat and cold pain thresh-
olds, mechanical detection and pain thresholds, pres-
ence of wind-up (enhanced temporal summation) to 
pinprick (online supplementary file 1).
3. Screening for psychological risk factors for acute and 
chronic pain using Hospital Anxiety and Depression 
Scale.39
4. Baseline assessment for delirium using the 3D-CAM 
instrument.40
5. Baseline assessment of serum inflammatory markers 
(IL-1β, IL-6, TNF-α, IL-10).
Interventions
Postoperatively, all patients will receive a standardised 
pain regimen including a hydromorphone PCA (initial 
settings of no bolus dose, 0.25 mg per demand dose, 
minimal interval dose time of 10 min), acetaminophen 
(1000 mg every 6 hours for 24 hours) and ketorolac 
(15 mg every 6 hours for 72 hours) per surgeon’s prefer-
ence. Study group patients will have an epidural bupiv-
acaine infusion beginning in the operating room (OR).
An epidural infusion of 0.125% bupivacaine starting at 
5 mL/hour (range of 5–8 mL/hour) will be started after 
induction of anaesthesia. Epidural narcotic consisting of 
fentanyl 50 μg will be administered with sterile precaution 
by the anaesthesia provider before starting the epidural 
infusion. Epidural boluses of 0.125% bupivacaine may be 
administered as guided clinically. A phenylephrine infu-
sion can be used to maintain adequate blood pressure 
maintaining mean arterial pressures (MAP) >60 mm Hg. 
The epidural infusion can be paused if vasopressor 
requirements exceed 1 μg/kg/min of phenylephrine or 
0.1 μg/kg/min of norepinephrine. The epidural infu-
sion is to be paused if haemodynamics become unstable, 
either due to excessive blood loss or MAP consistently 
below 60 mm Hg. The epidural infusion can be resumed 
when haemodynamics are stable.
The bupivacaine 0.125% epidural infusion is to be 
discontinued in the OR at the end of surgery and a stan-
dard epidural infusion of 0.1% bupivacaine at 4–6 mL/
hour will be started in the post-anaesthesia care unit 
(PACU). The epidural infusion is followed up by an Acute 
Pain Service in the postoperative period that will titrate 
the infusion based on the patients’ self-reported pain 
scores and MAP values.
outcomes
Primary outcomes
The primary study outcome is the postoperative 
consumption of opioids (measured in morphine or 
morphine-equivalents) in patients undergoing pancre-
atic resections in the control group compared with the 
study group. Each subject’s morphine or morphine-equiv-
alent consumption postoperatively will be assessed every 
24 hours. All subjects will be assessed daily during their 
postoperative inpatient admission by a trained member 
of the Acute Pain Service who is blinded to the treatment 
arm of the study.
Secondary outcomes
Secondary outcomes of the study include measures eval-
uated during the inpatient postoperative period as well 
as during subsequent outpatient follow-up. Study team 
members blinded to the treatment group of the patient 
will assess all secondary outcomes. Patient recovery and 
healing postoperatively will be evaluated using various 
measures, such as visual analogue scores, intravenous 
fluid requirements, anti-emetic doses and return of bowel 
function. Serum inflammatory markers will be evaluated 
serially, preoperatively on day of surgery, 3 hours after the 
start of surgical incision in the OR, on postoperative day 
2 (POD2) and at the initial postoperative visit 2–6 weeks 
after surgery. Postoperative delirium assessments will be 
performed when patients can be aroused sufficiently 
in order to be assessed for delirium (Richmond Agita-
tion-Sedation Scale > −4). Each patient will be assessed 
for delirium on POD2 as postoperative delirium typically 
first manifests 24–96 hours after surgery. For non-verbal 
patients, the Confusion Assessment Method for the Inten-
sive Care Unit (CAM-ICU) instrument will be used, and 
for verbal patients, the 3D-CAM instrument will be used.40 
As delirium is a fluctuating disorder and can be missed 
with sporadic delirium assessments, a structured method 
of chart review will be used to complement the clinical 
assessments.
This combined approach (3D-CAM interview or 
CAM-ICU plus chart review) increases the sensitivity 
and retains specificity in detecting incident delirium. 
The trial staff has undergone formal training in 
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clinical delirium assessment and on the chart review 
methodology.
Patients will be seen for their initial postoperative weeks 
at 2–6 weeks after hospital discharge and will undergo 
repeat PPSP evaluation at that time.
Patients will continue to be followed in clinic for 
2 years postoperatively with laboratory and radiolog-
ical evaluation as deemed appropriate by the primary 
surgeon. Patients will be followed for tumour recurrence 
and overall survival. Data will be collected directly from 
subject’s medical record; no study-specific procedures 
will be implemented at follow-up visits.
sample size
Sample size estimation was performed based on the study 
primary outcome of postoperative opioid consumption. 
Based on our prior experience, this estimation will be 
based on the following assumptions41: expected morphine 
consumption is 30 mg intraoperatively, 30 mg on post-
operative day 1 (POD1), 20 mg on POD2 and 10 mg on 
POD3. Therefore, expected total morphine consumption 
in the first 72 hours is, on average, 80 mg. Then, assuming 
that the SD of morphine consumption is 30 mg, that a 
20 mg difference in morphine consumption between 
groups is a clinically meaningful reduction of opioid use 
and assuming normal distribution of morphine consump-
tion in both patient groups, the proposed sample size 
for a=0.05 and b=0.2 would be 37 patients per group (74 
patients in total). However, we propose to increase the 
sample size of the study to 150 total patients to account 
for patients lost to follow-up, inability to complete the 
scheduled pancreatic resection, data errors and other 
unanticipated study problems.
recruitment
Participants will be recruited primarily through the 
Washington University Hepatobiliary-Pancreatic Surgery 
clinics. Subjects will be given verbal (initially) and then 
written descriptions of the study aims, procedures, risks 
and benefits, and will be required to give written informed 
consent. A member of the investigative team provides 
all study descriptions, informed consent and answers all 
questions. No deception is required for the purposes of 
this study. All subjects will be aware of the randomisation 
used in this study to either the control or intervention 
group. Subjects are informed verbally and in writing that 
participation is voluntary and they may refuse to partici-
pate and may withdraw from the study at any time without 
penalty.
Allocation
Participants will be randomised in a 1:1 ratio into the 
control group with standard of care pain management 
regimen or the intervention group with the addition 
of epidural analgesia. Randomisation will occur via 
randomised number generation.
This is a single-blind study. Patients and the primary 
investigative team will be aware of the randomisation. 
However, all study members performing data collection 
will be blinded to the randomisation.
data analysis and management
Data analysis for this study will focus on the compar-
ison of patient outcomes (postoperative morphine/
morphine-equivalent consumption, measures of post-
operative recovery, inflammatory markers, 3D-CAM/
CAM-ICU assessments, QST) between the intervention 
and control study groups. Based on data distribution, 
continuous variables will be compared between the two 
groups using Student’s t-test or the Mann-Whitney U test 
as appropriate. When appropriate, significance of find-
ings will be adjusted for multiple comparisons using the 
Bonferroni correction method.
The Center for Biomedical Informatics at Washington 
University will be used as the central location for data 
collection and management. Since 2008, Washington 
University has hosted Research Electronic Data Capture 
(REDCap), a secure, web-based application for building 
and storing online research and clinical trial databases. 
The REDCap servers are securely housed in an on-site 
limited access data centre managed by the Center for 
Biomedical Informatics at Washington University. All 
web-based information transmission is encrypted, and all 
data are stored on a private firewall-protected network. 
All users are assigned individual user IDs, and passwords 
and individual access is restricted on a role-specific 
basis. REDCap was developed specifically around Health 
Insurance Portability and Accountability Act (HIPAA) 
guidelines and is also implemented and maintained in 
accordance with institutional security guidelines.
Monitoring
The study team will monitor all study participants for 
adverse events. The PI will report all unanticipated prob-
lems or adverse events, all conditions of non-compliance 
and any new information that may affect the continued 
or current enrolment of study participants to the IRB. All 
events will be reported to the IRB within 10 working days 
of the event or of notification of the PI of the event. The 
death of a study participant must be reported to the IRB 
within one working day of the event or of notification of 
the PI of the event.
The specific monitoring plan for this investigation is 
commensurate with the risks and the size and complexity 
of the investigations planned. The potential risks are 
attributable to performing insertion of the epidural 
catheter and the use of bupivacaine for neuraxial anal-
gesia. Based on these considerations, the monitoring 
plan involves engaging a colleague from the Department 
of Anesthesiology not involved in the study to serve in 
a monitoring capacity. Based on the small size and rela-
tively low-risk nature of the protocol, only a third person 
(the colleague), rather than a full Data Safety Monitoring 
Board, will be used. The colleague will be an anaesthe-
siologist knowledgeable in the risks associated with 
nerve blocks and local anaesthetic administration. This 
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individual will review the annual summary of adverse 
events. In addition, this colleague will review all reports of 
a serious adverse event or an unexpected adverse event.
EthICs And dIssEMInAtIon
Ethics approval and consent
The E-PRO trial was provided ethical approval by the 
Washington University in St. Louis’s IRB which serves 
Washington University and Barnes-Jewish Hospital. Study 
recruitment and enrolment began in May 2016 and will 
continue through the end of 2017. Potential study partici-
pants will be given verbal and then written descriptions of 
the study aims, procedures, risks and benefits, and written 
informed consent will be obtained for all participants. All 
participants are informed verbally and in writing that 
participation is voluntary and they may refuse to partici-
pate and may withdraw from the study at any time without 
penalty.
Confidentiality
Only the investigators and research team will have access 
to any protected health information of study participants 
and any study data. All subjects will be assigned a study 
ID number. All study data and samples will be coded with 
the assigned study ID number. A key to the code linking 
code numbers to patient names will be kept at a separate 
location, under lock and key; this link will be destroyed at 
the conclusion of this study. All data will be recorded by a 
member of the research team and will be stored in a pass-
word-protected electronic database stored on the depart-
mental network drive. Study data will not be entered into 
participants’ medical records.
dissemination
Dissemination plans include presentations at scientific 
conferences and scientific publications.
ConClusIons
This trial investigates a wide spectrum of potential bene-
fits to patients undergoing pancreatic resection. During 
the initial postoperative period, the use of epidural anal-
gesia can aid in improving postoperative pain control, 
decreasing opioid consumption, reducing the incidence 
of delirium and expediting recovery. In addition to 
improving immediate postsurgical pain control, epidural 
analgesia may reduce the development of PPSP, which 
can persist for weeks to years after surgery. Lastly, epidural 
analgesia can help reduce the body’s stress response to 
a major operation, which has been linked to malignant 
progression and spread.
Based on this trial, we seek to establish the role of 
epidural analgesia as part of the standard of care in future 
patients undergoing pancreatic operations.
Contributors LMP and MMB are the primary authors of the E-PRO protocol. Their 
contributions include conceptualising the study design, drafting and editing the 
protocol, and creating the electronic database REDCap used for data collection. 
WGH contributed to the E-PRO protocol by editing the protocol and recruiting 
patients for enrolment. SH contributed to the E-PRO protocol by conceptualising 
the study design, drafting and editing the protocol, and supervising data collection. 
LW contributed to the E-PRO protocol by editing the protocol, recruiting patients 
and collecting data. MKu contributed to the E-PRO protocol by recruiting patients 
and collecting data. KF contributed to the E-PRO protocol and editing the protocol, 
creating the electronic database REDCap, coordinating patient enrolment and 
data collection. MKa contributed to the E-PRO protocol by conceptualising the 
study design and editing the protocol. RAS contributed to the E-PRO protocol by 
conceptualising the study design and editing the protocol. All authors have critically 
revised the E-PRO protocol and approved the final version. All authors agree to be 
accountable for the accuracy and integrity of all aspects of the E-PRO trial.
Funding QThis works was supported by the Foundation for Barnes-Jewish Hospital 
Project Award grant number 8083-88. 
Competing interests None declared.
Patient consent Obtained.
Ethics approval This study has been approved by the institutional review board at 
Washington University in St. Louis. 
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and 
analgesia on perioperative outcome: a randomized, controlled 
Veterans Affairs cooperative study. Ann Surg 2001;234:560–71.
 2. Choi DX, Schoeniger LO. For patients undergoing 
pancreatoduodenectomy, epidural anesthesia and analgesia 
improves pain but increases rates of intensive care unit admissions 
and alterations in analgesics. Pancreas 2010;39:492–7.
 3. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk 
factors and prevention. Lancet 2006;367:1618–25.
 4. Katz J, Seltzer Z. Transition from acute to chronic postsurgical 
pain: risk factors and protective factors. Expert Rev Neurother 
2009;9:723–44.
 5. Pogatzki-Zahn EM, Schnabel A, Zahn PK. Room for improvement: 
unmet needs in postoperative pain management. Expert Rev 
Neurother 2012;12:587–600.
 6. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol 
Clin 2007;45:27–37.
 7. DeVon HA, Piano MR, Rosenfeld AG, et al. The association of pain 
with protein inflammatory biomarkers: a review of the literature. Nurs 
Res 2014;63:61–2.
 8. Uçeyler N, Eberle T, Rolke R, et al. Differential expression 
patterns of cytokines in complex regional pain syndrome. Pain 
2007;132:195–205.
 9. De Jongh RF, Vissers KC, Meert TF, et al. The role of interleukin-6 in 
nociception and pain. Anesth Analg 2003;96:1096–103.
 10. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity 
and the generation of inflammatory pain. Proc Natl Acad Sci U S A 
1999;96:7723–30.
 11. Burger V, DOlimpio JT. Improving quality of life through pain control. 
Clin J Oncol Nurs 2013;17:117–8.
 12. Chan C, Franssen B, Domínguez I, et al. Impact on quality of life 
after pancreatoduodenectomy: a prospective study comparing 
preoperative and postoperative scores. J Gastrointest Surg 
2012;16:1341–6.
 13. Carroll J, Alavi K. Pathogenesis and management of postoperative 
ileus. Clin Colon Rectal Surg 2009;22:047–50.
 14. Leslie JB, Viscusi ER, Pergolizzi JV, et al. Anesthetic routines: the 
anesthesiologist’s role in GI recovery and postoperative ileus. Adv 
Prev Med 2011. doi: 10.4061/2011/976904. [Epub ahead of print 29 
Dec 2010]
 15. Person B, Wexner SD. The management of postoperative ileus. Curr 
Probl Surg 2006;43:6–65.
group.bmj.com on March 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Pak LM, et al. BMJ Open 2018;8:e018787. doi:10.1136/bmjopen-2017-018787
Open Access
 16. Emick DM, Riall TS, Cameron JL, et al. Hospital readmission after 
pancreaticoduodenectomy. J Gastrointest Surg 2006;10:1243–53.
 17. Ahmad SA, Edwards MJ, Sutton JM, et al. Factors influencing 
readmission after pancreaticoduodenectomy: a multi-institutional 
study of 1302 patients. Ann Surg 2012;256:529–37.
 18. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. 
Nature 2008;454:436–44.
 19. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, 
and migration in metastatic human pancreatic tumor cells expressing 
functional CXCR4. Cancer Res 2004;64:8420–7.
 20. McKay CJ, Glen P, McMillan DC. Chronic inflammation and 
pancreatic cancer. Best Pract Res Clin Gastroenterol 2008;22:65–73.
 21. Laird BJ, Scott AC, Colvin LA, et al. Cancer pain and its 
relationship to systemic inflammation: an exploratory study. Pain 
2011;152:460–3.
 22. Bar-Yosef S, Melamed R, Page GG, et al. Attenuation of the 
tumor-promoting effect of surgery by spinal blockade in rats. 
Anesthesiology 2001;94:1066–73.
 23. Liu S, Carpenter RL, Neal JM. Epidural anesthesia and 
analgesia. Their role in postoperative outcome. Anesthesiology 
1995;82:1474–506.
 24. Balcom JH, Rattner DW, Warshaw AL, et al. Ten-year experience 
with 733 pancreatic resections: changing indications, older 
patients, and decreasing length of hospitalization. Arch Surg 
2001;136:391–8.
 25. Winter JM, Cameron JL, Campbell KA, et al. 1423 
pancreaticoduodenectomies for pancreatic cancer: a single-
institution experience. J Gastrointest Surg 2006;10:1199–211.
 26. Matrisian L, Aizenberg R, Rosenzweig A. The alarming rise of 
pancreatic cancer deaths in the United States. http://www. pancan. 
org/ section_ research/ reports/ incidence_ report. php (accessed 13 Mar 
2014).
 27. Cress RD, Yin D, Clarke L, et al. Survival among patients with 
adenocarcinoma of the pancreas: a population-based study (United 
States). Cancer Causes Control 2006;17:403–9.
 28. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J 
Clin 2014;64:9–29.
 29. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer 
J Clin 2006;56:106–30.
 30. Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence 
after curative resection of pancreatic cancer, based on autopsy 
findings. J Gastrointest Surg 2006;10:511–8.
 31. Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and 
patterns of treatment failure in resected pancreatic adenocarcinoma. 
Arch Surg 2012;147:753–60.
 32. Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic 
adenocarcinoma: treating a systemic disease with systemic therapy. 
J Natl Cancer Inst 2014;106:dju011.
 33. Scavonetto F, Yeoh TY, Umbreit EC, et al. Association between 
neuraxial analgesia, cancer progression, and mortality after radical 
prostatectomy: a large, retrospective matched cohort study. Br J 
Anaesth 2014;113(Suppl 1):i95–102.
 34. Holler JP, Ahlbrandt J, Burkhardt E, et al. Peridural analgesia may 
affect long-term survival in patients with colorectal cancer after 
surgery (PACO-RAS-Study): an analysis of a cancer registry. Ann 
Surg 2013;258:989–93.
 35. Christopherson R, James KE, Tableman M, et al. Long-term survival 
after colon cancer surgery: a variation associated with choice of 
anesthesia. Anesth Analg 2008;107:325–32.
 36. Cummings KC, Xu F, Cummings LC, et al. A comparison of epidural 
analgesia and traditional pain management effects on survival 
and cancer recurrence after colectomy: a population-based study. 
Anesthesiology 2012;116:797–806.
 37. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia 
in the patient receiving antithrombotic or thrombolytic therapy: 
American Society of Regional Anesthesia and Pain Medicine 
Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 
2010;35:64–101.
 38. Finnerup NB, Sørensen L, Biering-Sørensen F, et al. Segmental 
hypersensitivity and spinothalamic function in spinal cord injury pain. 
Exp Neurol 2007;207:139–49.
 39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361–70.
 40. Ely EW. Vanderbilt University. Confusion assessment method for the 
ICU (CAM-ICU): the complete training manual. 2014. http://www. 
icudelirium. org/ docs/ CAM_ ICU_ training. pdf (accessed 14 Dec 2016).
 41. Mann C, Pouzeratte Y, Boccara G, et al. Comparison of intravenous 
or epidural patient-controlled analgesia in the elderly after major 
abdominal surgery. Anesthesiology 2000;92:433.
group.bmj.com on March 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
controlled trial
(E-PRO) study: protocol for a randomised 
Epidurals in Pancreatic Resection Outcomes
Michael M Bottros
Monika Kurtz, Karen Frey, Menelaos Karanikolas, Robert A Swarm and 
Linda Ma Pak, Simon Haroutounian, William G Hawkins, Lori Worley,
doi: 10.1136/bmjopen-2017-018787
2018 8: BMJ Open
 http://bmjopen.bmj.com/content/8/1/e018787




This article cites 38 articles, 2 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 8, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
